GGHC
STOK icon

Gilder Gagnon Howe & Co’s Stoke Therapeutics STOK Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.7M Buy
113,065
+438
+0.4% +$14.1K 0.04% 188
2026
Q1 		$3.67M Sell
112,627
-9,821
-8% -$322K 0.04% 167
2025
Q4 		$3.89M Sell
122,448
-32,718
-21% -$984K 0.04% 162
2025
Q3 		$3.65M Buy
155,166
+25,595
+20% +$439K 0.04% 169
2025
Q2 		$1.47M Buy
129,571
+23,754
+22% +$226K 0.02% 189
2025
Q1 		$704K Buy
105,817
+13,271
+14% +$124K 0.01% 196
2024
Q4 		$1.02M Buy
92,546
+1,791
+2% +$22K 0.01% 210
2024
Q3 		$1.12M Buy
90,755
+2,178
+2% +$30.9K 0.01% 204
2024
Q2 		$1.2M Sell
88,577
-1,206
-1% -$16.3K 0.02% 198
2024
Q1 		$1.21M Buy
89,783
+27,535
+44% +$167K 0.02% 206
2023
Q4 		$327K Sell
62,248
-11
-0% -$47 ﹤0.01% 233
2023
Q3 		$245K Buy
62,259
+11,185
+22% +$73.5K ﹤0.01% 246
2023
Q2 		$543K Sell
51,074
-863
-2% -$9.18K 0.01% 245
2023
Q1 		$433K Buy
51,937
+29,333
+130% +$265K 0.01% 225
2022
Q4 		$209K Sell
22,604
-35,260
-61% -$367K ﹤0.01% 236
2022
Q3 		$743K Sell
57,864
-445
-0.8% -$7.09K 0.01% 207
2022
Q2 		$770K Sell
58,309
-506,207
-90% -$7.69M 0.01% 209
2022
Q1 		$11.9M Sell
564,516
-507,924
-47% -$10.2M 0.11% 128
2021
Q4 		$25.7M Sell
1,072,440
-50,915
-5% -$1.22M 0.15% 126
2021
Q3 		$28.6M Sell
1,123,355
-122,601
-10% -$3.42M 0.15% 133
2021
Q2 		$41.9M Sell
1,245,956
-19,994
-2% -$707K 0.21% 113
2021
Q1 		$49.2M Sell
1,265,950
-204,891
-14% -$11.7M 0.27% 101
2020
Q4 		$91.1M Sell
1,470,841
-19,312
-1% -$885K 0.45% 70
2020
Q3 		$49.9M Sell
1,490,153
-79,411
-5% -$2.27M 0.31% 90
2020
Q2 		$37.4M Sell
1,569,564
-117,183
-7% -$2.78M 0.29% 90
2020
Q1 		$38.6M Sell
1,686,747
-140,143
-8% -$3.46M 0.46% 71
2019
Q4 		$51.7M Sell
1,826,890
-49,301
-3% -$1.24M 0.54% 66
2019
Q3 		$40.3M Buy
1,876,191
+14,568
+0.8% +$406K 0.46% 68
2019
Q2 		$54.3M Buy
+1,861,623
New +$50M 0.55% 63

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gilder Gagnon Howe & Co's STOK Position: Q2 2026 in Review

Gilder Gagnon Howe & Co increased its Stoke Therapeutics (STOK) stake by 0.39% in Q2 2026, buying an estimated $14.1K and bringing the position to 113,065 shares worth $3.7M. The position accounts for 0.04% of the portfolio, ranked #188.

Gilder Gagnon Howe & Co first reported a position in STOK in Q2 2019 and has held it in 29 quarters since. The position peaked at $91.1M in Q4 2020. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Gilder Gagnon Howe & Co held 113,065 shares of Stoke Therapeutics worth $3.7M as of Q2 2026.
  • Gilder Gagnon Howe & Co bought 438 Stoke Therapeutics shares in Q2 2026, an estimated $14.1K.
  • Stoke Therapeutics made up 0.04% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #188 holding.
  • Gilder Gagnon Howe & Co first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Gilder Gagnon Howe & Co's Stoke Therapeutics position peaked at $91.1M in Q4 2020.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.